Erythromycin Ethylsuccinate
16 NDCs across 5 manufacturers|10 Generic,6 Brand
Erythromycin Ethylsuccinate is used to treat acne vulgaris, campylobacter infections, chancroid, chlamydia infections, erythrasma and bacterial eye infections, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jan 1, 1982. FDA's Orange Book lists 10 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $4 million on Erythromycin Ethylsuccinate across 7,325 claims for 1,883 beneficiaries.
Erythromycin Ethylsuccinate is available as 16 NDCs from 5 manufacturers (10 generic, 6 brand), with NADAC prices from $0.91 to $6.31 per ML — the most expensive product costs about 6.9× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
16
10G / 6B
Manufacturers
5
competing in market
Price Spread
$0.91 – $6.31
per ML, 15 of 16 NDCs
7d Activity
avg -1.6% WoW · of 16 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
5 manufacturers producing ERYTHROMYCIN ETHYLSUCCINATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ERYTHROMYCIN ES 400 MG TAB | $11.7351 per EA | — |
ERYPED 400 MG/5 ML SUSPENSION | $6.3072 per ML | — |
ERYPED 400 MG/5 ML SUSPENSION | $6.3072 per ML | — |
ERYPED 200 MG/5 ML SUSPENSION | $3.6046 per ML | — |
E.E.S. 200 MG/5 ML SUSPENSION | $3.6046 per ML | — |
E.E.S. 200 MG/5 ML SUSPENSION | $3.6046 per ML | — |
E.E.S. 200 MG/5 ML GRANULES | $3.1656 per ML | — |
ERYTHROMYCIN 400 MG/5 ML SUSP | $1.7254 per ML | -1.30% |
ERYTHROMYCIN 400 MG/5 ML SUSP | $1.7254 per ML | -1.30% |
ERYTHROMYCIN 400 MG/5 ML SUSP | $1.7254 per ML | -1.30% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $1.5305 per ML | -2.44% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $1.5305 per ML | -2.44% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $0.9144 per ML | -1.29% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $0.9144 per ML | -1.29% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $0.9144 per ML | -1.29% |
ERYTHROMYCIN 200 MG/5 ML SUSP | $0.9144 per ML | -1.29% |
Frequently Asked Questions
What is Erythromycin Ethylsuccinate used to treat?
Erythromycin Ethylsuccinate is used to treat acne vulgaris, campylobacter infections, chancroid, chlamydia infections, erythrasma and bacterial eye infections, per the National Library of Medicine's MED-RT classification.
When did Erythromycin Ethylsuccinate become available as a generic?
FDA approved the first generic Erythromycin Ethylsuccinate (ANDA) on Jan 1, 1982. The Orange Book currently lists 10 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Erythromycin Ethylsuccinate?
In 2024, Medicare Part D spent $4 million on Erythromycin Ethylsuccinate across 7,325 claims for 1,883 beneficiaries.
How many Erythromycin Ethylsuccinate products are on the market?
The Erythromycin Ethylsuccinate drug market contains 16 NDCs from 5 manufacturers — 10 generic and 6 brand products.
What is the price range for Erythromycin Ethylsuccinate?
NADAC reference prices for Erythromycin Ethylsuccinate range from $0.9144 to $6.3072 per ML — the most expensive product costs about 6.9× the cheapest. 1 additional product is priced per a different unit (e.g. liquids per ML) and isn't directly comparable.
Is generic Erythromycin Ethylsuccinate cheaper than brand?
The average generic NADAC for Erythromycin Ethylsuccinate is $1.3217 per ML, versus $4.4323 for brand-labeled products — brand versions average about 3.4× the generic price.
Which manufacturers make Erythromycin Ethylsuccinate?
5 manufacturers list Erythromycin Ethylsuccinate in NADAC. Ranked by number of NDCs, the largest are Azurity Pharmaceuticals Inc. (5), Wilshire Pharmaceuticals Inc. (4), ANI Pharmaceuticals, Inc. (3), Carnegie Pharmaceuticals LLC (2), Nivagen Pharmaceuticals Inc. (2).
How has the price of Erythromycin Ethylsuccinate changed recently?
Over the past 7 days, 0 Erythromycin Ethylsuccinate NDCs rose and 18 fell, with a market-wide average change of -1.6%.